ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 1606 - 1620 of 5508 products
Harbour BioMed to Begin US Trials of CLTA-4 Antibody
$5.00
Available
MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor
$5.00
Available
Gilead Starts Two Phase III Trials of Remdesivir for COVID-19
$5.00
Available
Ascletis Begins China Trial of Combo Treatment for COVID-19
$5.00
Available
Harbour BioMed Approved to Start US Trials of PD-L1 in Orphan Disease
$5.00
Available
Harvard and Guangzhou Institute of Respiratory Health Form $115 Million COVID-19 Collaboration
$5.00
Available
Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
$5.00
Available
Moderna Ships Coronavirus Vaccine for Clinical Trials
$5.00
Available
WuXi Biologics and Vir Biotech Team up to Develop COVID-19 Antibodies
$5.00
Available
CICC Capital Closes $229 Million Fund for China Biologic Investments
$5.00
Available
Invetx Raises $15 Million from Anterra, AbCellear and WuXi Biologics
$5.00
Available
Clover Collaborates with GSK on COVID-19 Vaccine
$5.00
Available
Ascentage Approved to Start China Trial of Apoptosis Candidate for Pancreatic Cancer
$5.00
Available
Shanghai ImmuneOnco Raises $6.4 Million for Immunotherapies
$5.00
Available
WuXi Vaccines Signs $3 Billion, 20-Year Agreement to Manufacture Vaccine
$5.00
Available